Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes

AIM: To evaluate, using post hoc analyses, whether the novel combination of a basal insulin, insulin degludec, and a glucagon‐like peptide‐1 receptor agonist, liraglutide (IDegLira), was consistently effective in patients with type 2 diabetes (T2D), regardless of the stage of T2D progression. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodbard, H. W., Buse, J. B., Woo, V., Vilsbøll, T., Langbakke, I. H., Kvist, K., Gough, S. C. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063148/
https://www.ncbi.nlm.nih.gov/pubmed/26343931
http://dx.doi.org/10.1111/dom.12574

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063148/
https://www.ncbi.nlm.nih.gov/pubmed/26343931
http://dx.doi.org/10.1111/dom.12574

Ejemplares similares